Globus Medical Inc GMED
- Employees
- 6,000
- Headquarters
- Audubon, PA
- Next results
- around Jan 6, 2027
Where each dollar of revenue went, FY2025
Revenue of $2.9B through the costs to a net profit of $537.9M · income statement of the 10-K
GMED among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
9 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 24, 2026 against Feb 20, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Critical audit matters changedNew this year: Business Combinations - Nevro Merger (“On April 3, 2025, the Company completed its merger with Nevro Corp. (“Nevro Merger”) with Nevro Corp. surviving as a wholly owned subsidiary of the Company, for total consideration of approximately $252.5 million. Management accounted for the acquisition as a business combination using the acquisiti”). Same as last year: Inventories Valuation
-
Receivables +21.7% ($557.7M to $678.9M) vs revenue +16.7% ($2.5B to $2.9B), +5.1 pts apart
9 more checks with nothing to note
-
Cash from operations $753.4M vs net income $537.9M (FY ending Dec 31, 2025)
-
Inventory +15.2% ($659.2M to $759.3M) vs revenue +16.7% ($2.5B to $2.9B), -1.5 pts apart
-
Same auditor in both 10-Ks: DELOITTE & TOUCHE LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
9 paragraphs in Risk Factors that were not in the 10-K filed Feb 20, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
Additionally, during 2025, Daniel Scavilla, our former Chief Executive Officer, resigned from the Company and was replaced by Mr. Pfeil, who had previously served as the Chief Operating Officer and Chief Financial Officer. Although the Board is confident in the leadership of Mr. Pfeil, leadership transitions can be inherently difficult…
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
In 2025, the U.S. enacted the imposition of widespread and substantial tariffs on imports, which resulted in the imposition of reciprocal or retaliatory tariffs and continued tariff volatility and uncertainty. The tariffs enacted by the U.S. included a universal baseline tariff of 10%, plus an additional country-specific tariff for…
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
The Company’s Bylaws provide, to the fullest extent permitted by law, that the Court of Chancery of the State of Delaware will be the exclusive forum for certain legal actions between the Company and its stockholders, which could increase costs to bring a claim, discourage claims or limit the ability of the Company’s stockholders to…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $1.0B | $1.6B | $2.5B | $2.9B |
| Net income | $190.2M | $122.9M | $103.0M | $537.9M |
| Operating cash flow | $178.5M | $243.5M | $520.6M | $753.4M |
| Free cash flow | $104.4M | $165.2M | $405.2M | $588.8M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$2.9B ▲ 16.7% in FY2025$537.9M ▲ 422.3% in FY2025$588.8M ▲ 45.3% in FY2025
Recent filings
5 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 10, 2026TOBIN JAMES R (Director) gave notice of a planned sale of 41,666 shares worth about $3.1M Form 144, approximate sale date Nov 10, 2026
-
Planned saleNov 5, 2026Kyle R. Kline (Chief Financial Officer and Senior Vice President) adopted a 10b5-1 trading plan reported in the 10-Q, up to 25,493 shares, runs to Nov 30, 2027
-
8-KNov 5, 2026Quarterly results, Other events 8-K items 2.02, 8.01
-
10-QNov 5, 2026Quarterly report (10-Q) period ended Sep 30, 2026
-
Planned saleNov 4, 2026RHOADS ANN D (Director) gave notice of a planned sale of 5,000 shares worth about $425K Form 144, approximate sale date Nov 4, 2026, under a 10b5-1 plan adopted Jun 10, 2026
About the company
Globus Medical Inc, Audubon, PA · from the 10-K filed Feb 24, 2026
Globus Medical, Inc. (together, as applicable, with its consolidated subsidiaries, “Globus,” the “Company,” “we,” “us” or “our”), headquartered in Audubon, Pennsylvania, is a medical device company that develops and commercializes healthcare solutions whose mission is to improve the quality of life of patients with musculoskeletal disorders. Founded in 2003, Globus is committed to medical device innovation and delivering exceptional service to hospitals, ambulatory surgery centers and physicians to advance patient care and improve efficiency.
- Headquarters
- Audubon, PA
- Country
- United States
- Reports in
- USD
- Listed on
- NYSE
- Fiscal year ends
- December 31
- Last results
- Nov 5, 2026
- Incorporated in
- DE
Employees, at the top of the page: "As of December 31, 2025, we had over 6,000 employees worldwide, including sales and marketing, product development, operations, general administrative and accounting, both domestically and internationally" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 20, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GMED/export.csv") into a cell.